Abstract
IntroductionPrevious research has demonstrated a correlation among patient preferences, dosing burden, and medication nonadherence, a well-recognized challenge in type 2 diabetes mellitus (T2DM). The objective of this study was to elicit preferences for alternative dosing regimens for oral antihyperglycemic therapies among patients with T2DM and to quantify differences in dosing preferences among patients with different characteristics.MethodsPreferences for dosing of oral antihyperglycemic drugs (OAD) were evaluated by surveying patients with T2DM in the United States (US). Survey participants were adult US patients with T2DM who were taking no or only 1 OAD and no injectable therapies. Each patient completed a web-enabled discrete-choice experiment (DCE) including a series of 8 pairs of hypothetical OAD profiles. Each profile was defined by reductions in average glucose, dosing schedule (e.g., once-weekly, once-daily, or twice-daily dosing), chance of mild-to-moderate gastrointestinal side effects, frequency of hypoglycemia, weight change, incremental risk of congestive heart failure, and cost. Each participant also answered a direct question about dosing preference. Random-parameters logit was used to analyze the DCE data. Prespecified subgroups were analyzed.ResultsOf 2,262 patients invited to participate, 923 were included in the analysis (mean age 63 years, 45% male, 79% white). Reducing dosing frequency was statistically significantly important to patients; however, it was relatively less important than medication cost or clinical outcomes. On average, patients preferred once-weekly to once-daily dosing. Patients not currently taking an OAD had a stronger preference for once-weekly dosing than patients on treatment (P = 0.012). Patients younger than 45 years had a stronger preference for weekly dosing than older patients (P < 0.075).ConclusionsFor younger patients and patients not currently on treatment, once-weekly dosing may provide additional incentive to initiate and adhere to antihyperglycemic treatment; however, additional research will be required to confirm this hypothesis.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-015-0094-2) contains supplementary material, which is available to authorized users.
Highlights
Previous research has demonstrated a correlation among patient preferences, dosing burden, and medication nonadherence, a well-recognized challenge in type 2 diabetes mellitus (T2DM)
A recent study demonstrated that patients with T2DM have preferences for reducing the dosing burden of combination oral antihyperglycemic drugs (OADs) therapy and that patients with lower current overall medication burden were more likely to indicate that decreases in dosing burden would result in an improvement in their expected medication adherence [7]
All attributes used to describe T2DM medications were important to patients
Summary
Previous research has demonstrated a correlation among patient preferences, dosing burden, and medication nonadherence, a well-recognized challenge in type 2 diabetes mellitus (T2DM). Discrete-choice experiments (DCEs), known as choice-format conjoint analysis studies, increasingly have been used to determine the tradeoffs that patients are willing to make among features of medical interventions [13,14,15] This method is based on the premise that medical interventions are composed of a set of attributes or outcomes, that the attractiveness of a particular intervention to an individual is a function of these attributes, and that choices among alternatives reveal patients’ relative preferences for these attributes [16]. A recent study demonstrated that patients with T2DM have preferences for reducing the dosing burden of combination OAD therapy and that patients with lower current overall medication burden were more likely to indicate that decreases in dosing burden would result in an improvement in their expected medication adherence [7]. The objective of the current study was to elicit preferences for alternative dosing regimens for OAD therapies among patients with T2DM and to quantify differences in dosing preferences among patients with different characteristics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
